ClinicalTrials.gg
CompletedNCT02807077Updated Oct 22, 2018

PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects

A Phase 1 interventional study of Pacritinib in Myelofibrosis, sponsored by CTI BioPharma. Completed at 3 sites in 3 countries. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-22.

Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing pacritinib in Primary Myelofibrosis — 6 open to participants now, 8 under way, 1 of them phase 3. pacritinib · Primary Myelofibrosis.

Enrollment
9th of 18
40 · median 35
Started
2014
with 1 other
Phase 1
5 of 18
2 open now
Registered
8th of 18
by date
Lead sponsor
5 of 18
CTI BioPharma

Among the 18 studies testing pacritinib in Primary Myelofibrosis, this one is the 9th largest by enrollment, is one of 2 that started in 2014, is one of 5 in phase 1, and was the 8th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

6 of the 18 studies testing pacritinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pacritinib

pacritinib: first FDA approval 2022 (VONJO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing pacritinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This is a Phase 1 open label, single dose, 5 parallel-group study in which a single 400 mg dose of pacritinib will be administered orally to patients with renal impairment (mild, moderate, severe, and patients with ESRD requiring hemodialysis) and sex-, age- and weight-matched healthy subjects.Patients with ESRD will receive a single 400 mg dose of pacritinib during 2 different treatment periods: Dialysis and Inter-Dialysis. The primary objective of the study is to evaluate the pharmacokinetics and safety of pacritinib in renal impairment.

Read the detailed description

Groups 1, 2, and 3 will consist of 8 patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease [MDRD] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.

Group 4 will consist of 8 patients with ESRD requiring hemodialysis who have been on a stable dialysis regimen for at least 6 months. In this cohort only, patients will participate in 2 treatment periods, Dialysis and Inter-Dialysis, separated by a 14-day period between pacritinib administration. In the Dialysis Treatment Period, a single 400 mg dose of pacritinib will be administered 4 hours prior to each patient's normally scheduled hemodialysis. In the Inter-Dialysis Treatment Period, a single 400 mg dose of pacritinib will be administered immediately after the end of the patient's normally scheduled hemodialysis session.

Group 5 will consist of 8 healthy subjects enrolled to match the sex-, age-, and weight of the patients with mild, moderate, and severe renal impairment and patients with ESRD enrolled in the study. Healthy subjects will be administered a single 400 mg dose of pacritinib.

03

Conditions studied

  • Myelofibrosis

Browse trials for

Keywords

  • Healthy subjects
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Study Participants

  1. Male and/or female participants aged 18 to 85 years (inclusive)
  2. Male, non-fertile female or female of using a medically approved method

    • Females must be non-pregnant and non-lactating, and females not of childbearing potential must be for at least 1 year or surgically sterile (e.g., tubal ligation, hysterectomy) for at least 90 days, or agree to use contraception from the time of signing the or 10 days prior to Check-in (Day -1) until 30 days after Study Completion. One of the following forms of contraception must be used from the time of signing the informed consent or 10 days prior to Check-in (Day -1) until 14 days after the final dose administration: non-hormonal intrauterine device (IUD) with spermicide; female condom with spermicide; contraceptive sponge with spermicide; intravaginal system (e.g.,NuvaRing®); diaphragm with spermicide; cervical cap with spermicide; male sexual partner who agrees to use a male condom with spermicide; sterile sexual partner; or abstinence. Oral, implantable, transdermal, or injectable contraceptives may not be used from the time of signing the informed consent or 10 days prior to Check-in (Day -1) until 14 days after the final dose administration. For all females, the pregnancy test result must be negative at Screening and Check-in (Day -1)
    • Males will be sterile, or completely abstain from sexual intercourse, or agree to use, from Check-in (Day -1) until 90 days following Study Completion/ET, one of the following approved methods of contraception: male condom with spermicide; sterile sexual partner; or use by female sexual partner of an IUD with spermicide; a female condom with spermicide; a contraceptive sponge with spermicide; an intravaginal system; a diaphragm with spermicide; a cervical cap with spermicide; or oral, implantable, transdermal, or injectable contraceptives. Participants will refrain from sperm donation from Check-in (Day -1) until 90 days following Study Completion
  3. (BMI) 18-33kg/m2 (inclusive) at Screening
  4. Negative test for selected drugs of abuse (including alcohol) at Screening and at Check-in (Day - 1) for Groups 1-3 and 5. Negative test for selected drugs of abuse (including alcohol) is only required at Screening in Group 4
  5. Negative hepatitis panel (including surface antigen [HBsAg] and virus antibody [anti HCV]) and negative (HIV) antibody screens
  6. Able to communicate well with the investigator, to understand and comply with the requirements of the study. Understand and sign the written informed consent. Legal authorized representatives are not permitted

    Patients with Renal Impairment Only

    In addition to the inclusion criteria specified for "All Study Participants" above, patients with renal impairment must meet the following criteria:

  7. Have stable renal disease without evidence of progressive renal disease (i.e. no known significant change of for 12 weeks)

    • mild renal impairment: eGFR 60-89 mL/min/1.73 m2
    • moderate renal impairment: eGFR 30-59 mL/min/1.73 m2
    • severe renal impairment: from eGFR 15-29 mL/min/1.73 m2
    • ESRD: requiring dialysis and have been on a stable dialysis regimen for at least 6 months

    Renal function will be determined from Screening serum creatinine value using the MDRD Study equation

  8. Vital signs (after 5 minutes resting measured in the supine position) within the following ranges as guidance for the Investigator:

    • oral body temperature between 35.0-37.8 °C
    • systolic blood pressure, 95-180 mm Hg
    • diastolic blood pressure, 55-95 mm Hg
    • pulse rate, 50-95 bpm

    Blood pressure and pulse will be taken again in a standing position. After 3 minutes standing, there shall be no more than a 20 mm Hg drop in systolic or 10 mm Hg drop in diastolic blood pressure associated with symptomatic postural hypotension

    Healthy Subjects Only

    In addition to the inclusion criteria specified for "All Study Participants" above, healthy subjects must meet the following criteria:

  9. No history or clinical manifestation of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal (e.g., celiac disease, peptic ulcer, gastro esophageal reflux, inflammatory bowel disease), metabolic, allergic, dermatological, neurological, or psychiatric disorder (as determined by the Investigator; appendectomy and cholecystectomy are not considered to be clinically significant disease)
  10. Normal renal function, eGFR ≥90 mL/min/1.73m2 (determined by Screening serum creatinine using the MDRD Study equation)
  11. Matched with all enrolled patients with renal impairment for age classes in the 0-25, 26-50, 51-75, and 76-100 percentiles of age distribution
  12. Matched with all enrolled patients with renal impairment for weight (BMI) classes in the 0-25, 26-50, 51-75, and 76-100 percentiles of BMI distribution
  13. Matched according to the sex distribution of all enrolled patients with renal impairment
  14. Vital signs (after 5 minutes resting measured in the supine position) within the following ranges as guidance for the Investigator:

    • oral body temperature between 35.0-37.5 °C
    • systolic blood pressure, 90-160 mm Hg
    • diastolic blood pressure, 50-100 mm Hg
    • pulse rate, 45-90 bpm

Blood pressure and pulse will be taken again in a standing position. After 3 minutes standing, there shall be no more than a 20 mm Hg drop in systolic or 10 mm Hg drop in diastolic blood pressure associated with symptomatic postural hypotension

Exclusion criteria

Exclusion Criteria:

All Study Participants

Participants meeting any of the following criteria will be excluded from entry into or continuation in the study unless sponsor approval is obtained:

  1. Pregnant or lactating female
  2. Renal transplant at any time
  3. Liver cirrhosis or a positive surface antigen (HBsAg) or antibody test result
  4. History of immunodeficiency diseases, including a positive antibody test result
  5. Acute renal failure
  6. History of chronic or recurrent urinary tract infection active within the past 30 days
  7. History of pelvic irradiation within the past 30 days
  8. Alcohol related hepatic disease
  9. History of except the following: cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps
  10. Any of the following within the past 6 months:

    • myocardial infarction (MI) (if the Screening reveals patterns consistent with a MI and the date of the event cannot be determined, then the subject can enter the study at the discretion of the Investigator and/or local medical monitor, with sponsor's permission)
    • coronary artery bypass surgery or percutaneous coronary intervention
    • unstable angina or stroke
  11. Past medical history of ECG abnormalities, presence of an abnormal ECG (which in the Investigator's opinion is clinically significant), >450 msec, or has concomitant conditions that increase risk for QTc interval prolongation (e.g., heart failure, hypokalemia [defined as serum potassium \<3.0mEq/L that is persistent and to correction], or family history of long QT interval syndrome)
  12. History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator
  13. Any medical or surgical conditions that might significantly interfere with the gastrointestinal absorption, distribution, metabolism, or excretion of the drug. This includes any history of a significant disease of the gastrointestinal tract, pancreas, liver, kidneys, and/or blood-forming organs. It does not include appendectomy, cholecystectomy, hernia repair, or underlying renal disease or abnormalities that occur as a direct result of renal disease in the renal impairment patients or abnormalities that occur as a direct result of renal disease
  14. History of drug or alcohol abuse within the last 6 months, or evidence of recent drug or alcohol abuse as indicated by laboratory assays conducted during screening or baseline evaluations
  15. Heavy use of tobacco- or nicotine-containing products within 6 months prior to Check-in (Day -1) and during the entire study, defined as urinary cotinine > 150 ng/mL
  16. Consumption of alcohol- or caffeine-containing foods and beverages for 72 hours prior to screening and during the entire study
  17. Consumption of grapefruit-containing foods and beverages or other potent cytochrome P450 (CYP)3A4 inhibitors or inducers for 7 days prior to Check-in (Day -1) and during the entire study
  18. Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 half-lives or 30 days prior to Check-in (Day -1), whichever is longer, and during the entire study
  19. Use of oral, implantable, injectable, or transdermal within 10 days prior to Check-in (Day -1) or from the time of signing the (females only) until 14 days after the final dose administration
  20. Use of any over-the-counter, non-prescription medications, vitamins, or minerals (except as prescribed by a physician), within 14 days prior to Check-in (Day -1) and during the entire study
  21. Use of phytotherapeutic/herbal/plant-derived preparations within 14 days prior to Check-in (Day -1) of and during the entire study
  22. Use of potent inducers of within 30 days of Check-in (Day -1)
  23. Use of potent inhibitors of CYP3A4 within 15 days of Check-in (Day -1)
  24. Poor peripheral venous access
  25. Donation or loss of 400 mL or more of blood or plasma within 8 weeks prior to Check-in (Day -1) and through entire study
  26. Receipt of blood products within 2 months prior to Check-in (Day -1)
  27. Any diarrhea or vomiting during the Screening period or at Check-in (Day -1)
  28. Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study
  29. Any of the following concomitant medications within 30 days of Check-in (Day -1) (unless cited otherwise below):

    • potassium-sparing diuretics e.g. spironolactone, triamterene, amiloride (within 14 days of Check-in)
    • class Ia, Ib and Ic or III anti-arrhythmics
    • probenecid
    • any medication that is in moderate or severe renally impaired population
    • any drug with a known and frequent toxicity to a major organ system within 3 months of Screening (i.e., cytostatic drugs)
  30. Any of the following (repeated and confirmed) laboratory abnormalities at Screening or Check-in:

    • Clinically significant (as judged by the Investigator in consultation with the Sponsor) laboratory abnormalities except elevated blood urea nitrogen (BUN), elevated serum creatinine, hyperglycemia, and/or glycosuria
    • (ALT)>1.5xULN
    • Aspartate aminotransferase (AST)>1.5xULN
    • Total >1.3x (unless due to Gilbert's Syndrome)
    • \< 8 g/dL

    Laboratory testing may be repeated once prior to dosing (to rule out any possible laboratory error)

  31. Planned surgery during the study period
  32. Subjects who are deemed vulnerable by way of imprisonment, remand or detention

    Patients with Renal Impairment Only

    In addition to the exclusion criteria specified for "All Subjects" above, any patient with renal impairment who meets the following criteria will be excluded from entry into the study:

  33. Any condition that would compromise patients' safety during study participation
  34. Participants in Groups 1-3: Difficulty voiding or urinary tract obstruction at Check-in or undergoing any method of dialysis (hemodialysis, peritoneal dialysis)
  35. Screening physical exam or ECG finding considered of clinical significance by the Investigator, or a laboratory evaluation outside of the normal reference range with the exception of values that are related to renal impairment
  36. Any significant acute or chronic disease (except renal impairment) which is unstable or can interfere with the objectives of the study
  37. Any change in stable dose regimens, either over-the-counter or prescription, for chronic medical conditions (e.g. diabetes, dyslipidemia, renal impairment) within 4 weeks preceding dosing

    Healthy Subjects Only

    In addition to the exclusion criteria specified for "All Study Participants" above, any healthy subject who meets the following criteria will be excluded from entry into the study:

  38. Any screening or baseline physical exam, EKG, or laboratories outside the normal range and deemed clinically significant by the Investigator. Results deemed not clinically significant by the Investigator in consultation with the Sponsor are allowable.
  39. Use of any prescription medications and/or products within 14 days prior to Check-in (Day -1) and during the entire study
  40. History of renal impairment
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Subjects with mild renal impairment

    Group 1, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease \[MDRD\] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.

    Drug: Pacritinib

  • Experimental
    Subjects with moderate renal impairment

    Group 2, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease \[MDRD\] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.

    Drug: Pacritinib

  • Experimental
    Subjects with severe renal impairment

    Group 3, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease \[MDRD\] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.

    Drug: Pacritinib

  • Experimental
    Subjects with ESRD

    Group 4, will consist of patients with ESRD requiring hemodialysis who have been on a stable dialysis regimen for at least 6 months. In this cohort only, patients will participate in 2 treatment periods, Dialysis and Inter-Dialysis, separated by a 14-day period between pacritinib administration. In the Dialysis Treatment Period, a single 400 mg dose of pacritinib will be administered 4 hours prior to each patient's normally scheduled hemodialysis. In the Inter-Dialysis Treatment Period, a single 400 mg dose of pacritinib will be administered immediately after the end of the patient's normally scheduled hemodialysis session.

    Drug: Pacritinib

  • Experimental
    Healthy subjects

    Group 5, will consist of 8 healthy subjects enrolled to match the sex-, age-, and weight of the patients with mild, moderate, and severe renal impairment and patients with ESRD enrolled in the study. Healthy subjects will be administered a single 400 mg dose of pacritinib.

    Drug: Pacritinib

Interventions

  • Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis

06

What researchers measure

Primary outcomes

  1. The maximum plasma concentration (Cmax)

    The following pharmacokinetic parameters of pacritinib and major human metabolites were assessed following 400 mg single-dose administration of pacritinib capsule in patients with renal impairment and matched healthy subjects

    Time frame: Plasma: 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose. Urine- 0-168 hr interval

  2. The time to reach maximum plasma concentration (tmax)

    The following pharmacokinetic parameters of pacritinib and major human metabolites were assessed following 400 mg single-dose administration of pacritinib capsule in patients with renal impairment and matched healthy subjects

    Time frame: Plasma: 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose. Urine- 0-168 hr interval

  3. The area under the plasma concentration-time curve from time zero to time of the last measured concentration above the limit of quantification (AUC0-t).

    The following pharmacokinetic parameters of pacritinib and major human metabolites were assessed following 400 mg single-dose administration of pacritinib capsule in patients with renal impairment and matched healthy subjects

    Time frame: Plasma: 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose. Urine- 0-168 hr interval

  4. The area under the plasma concentration-time curve from zero to infinity (AUC0-∞)

    The following pharmacokinetic parameters of pacritinib and major human metabolites were assessed following 400 mg single-dose administration of pacritinib capsule in patients with renal impairment and matched healthy subjects

    Time frame: Plasma: 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose. Urine- 0-168 hr interval

  5. The apparent terminal elimination rate constant (λZ) and the respective apparent terminal elimination half-life (t½)

    The following pharmacokinetic parameters of pacritinib and major human metabolites were assessed following 400 mg single-dose administration of pacritinib capsule in patients with renal impairment and matched healthy subjects

    Time frame: Plasma: 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose. Urine- 0-168 hr interval

  6. The apparent volume of distribution (Vd)

    The following pharmacokinetic parameters of pacritinib and major human metabolites were assessed following 400 mg single-dose administration of pacritinib capsule in patients with renal impairment and matched healthy subjects

    Time frame: Plasma: 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose. Urine- 0-168 hr interval

  7. The apparent total body clearance (CL/F)

    The following pharmacokinetic parameters of pacritinib and major human metabolites were assessed following 400 mg single-dose administration of pacritinib capsule in patients with renal impairment and matched healthy subjects

    Time frame: Plasma: 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose. Urine- 0-168 hr interval

Secondary outcomes

  1. Incidence of Treatment emergent Adverse Events

    Adverse events, vital signs, physical examinations, clinical laboratory evaluations, and ECGs

    Time frame: Day 1 to Day 8

07

Study locations

3 sites
  • APEX GmbH
    Munich, D-81241, Germany
  • Republican Clinical Hospital
    Chisinau, MD-2025, Moldova, Republic of
  • Carol Davila Nephrology Hospital Bucharest
    Bucharest, Romania
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2016
First posted
Jun 21, 2016
Start
Nov 2014
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Last update
Oct 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02807077
Lead sponsor
CTI BioPharma
Collaborators
SGS S.A.
Responsible party
Sponsor
First posted
Jun 21, 2016
Start date
Nov 2014
Primary completion
Jul 2015
Completion
Jul 2015
Last update
Oct 22, 2018

Study contacts

Igor Codreanu, MD
principal investigator · Republican Clinical Hospital
Gernot Klein, MD
principal investigator · APEX GmbH
Mircea N Penescu, MD
principal investigator · Carol Davila Nephrology Hospital Bucharest
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pacritinib

Start the discussion